Benefits
Exercise-induced gut permeability
This is the most-studied use, and it is still unsettled. In a 12-person crossover trial, two weeks of colostrum before a hard run cut the usual post-exercise rise in a urinary sugar marker of gut leakiness by roughly 80 percent (0.38 to 0.49, against 0.38 to 0.92 on placebo), and an 8-person crossover trial from overlapping authors found a similar reduction of about 70 percent. A 2024 pooled analysis of 10 trials in athletes and patients found an overall drop in that marker (mean difference -0.24), but the trials disagreed with one another almost completely, and a blood marker of intestinal cell damage showed no difference at all. Pulling the other way, the largest and longest trial, 30 men running three times a week for eight weeks, found the marker rose more on 60 grams a day of colostrum than on whey protein or on nothing. The proposed mechanism, growth-factor support of tight-junction proteins, comes from cell work rather than from people.
Upper respiratory illness in athletes
One pooled analysis of 5 trials in 152 active adults reported 44 percent fewer days with upper respiratory symptoms and 38 percent fewer symptom episodes over 8 to 12 weeks. Read it with its own caveats: the authors rated 4 of the 5 trials at moderate or high risk of bias, and there were too few data to pool symptom duration at all. The usual explanation offered is mucosal IgA support, but a separate pooled analysis of 10 trials in 239 trained adults found little to no change in salivary IgA, serum IgG or IgA, lymphocytes or neutrophils, so the mechanism behind the symptom-day finding is unresolved.
NSAID-induced gastrointestinal damage
A human study found that taking bovine colostrum alongside an NSAID blunted the acute rise in gut permeability the drug normally causes, with growth-factor support of epithelial repair as the proposed mechanism. The evidence is limited to small, short studies in volunteers, and colostrum is not a treatment for ulcers or any diagnosed digestive condition.
Pediatric and infectious diarrhea
Hyperimmune bovine colostrum, made by vaccinating the cow against a specific pathogen such as rotavirus or ETEC, is a different product from the standard colostrum sold as a supplement, and it is the version with the stronger trial record in infectious diarrhea in children. Results with standard colostrum are more modest. This is targeted medical use under care rather than a reason to reach for a colostrum powder: acute diarrhea, especially in a child, needs oral rehydration and a doctor, and the WHO does not list colostrum as primary management.
Athletic recovery and performance — mixed evidence
Multiple trials test colostrum for muscle recovery, performance, and body composition. Results inconsistent — some show modest improvements in recovery markers, others null. Effect sizes smaller than for gut/immune endpoints. More plausible primary mechanism: protecting against exercise-induced gut barrier disruption rather than direct anabolic effects.
Mechanism of action
Immunoglobulin passive immunization
IgG is the most abundant component (~20-40% of total protein in standardized products). Orally administered bovine IgG is partially resistant to gastric digestion and reaches the intestinal lumen where it can bind pathogens, neutralize toxins, and modulate luminal immune responses. Bovine IgG has structural cross-reactivity with several human-relevant pathogens including rotavirus, E. coli adhesins, and some respiratory viruses. Most absorbed bovine IgG is degraded; the dominant therapeutic mechanism is luminal rather than systemic.
Growth factors and gut epithelial integrity
Bovine colostrum contains substantial concentrations of IGF-1, IGF-2, TGF-α, TGF-β, and EGF. These growth factors stimulate enterocyte proliferation, support tight junction protein expression (occludin, claudins, ZO-1), and induce heat shock protein 70 (HSP70) — providing cellular protection against thermal and oxidative stress. Colostrum-induced HSP70 was blocked by EGF receptor neutralizing antibody, identifying EGF signaling as a primary mechanism. Local gut effects appear primary; systemic IGF-1 increases from oral colostrum are minimal because the protein is largely digested.
Lactoferrin antimicrobial and iron-modulating activity
Lactoferrin (5-15 mg/g in standardized colostrum) is an iron-binding glycoprotein with broad antimicrobial activity. Iron sequestration starves iron-dependent pathogens; direct membrane disruption affects others. Lactoferrin also modulates innate immune cell activity and has anti-inflammatory effects on gut mucosa. Some commercial colostrum products are specifically standardized to lactoferrin content for this reason.
Antimicrobial peptides and proline-rich polypeptides
Lactoperoxidase, lysozyme, defensins, and proline-rich polypeptides (PRPs) provide additional antimicrobial activity and immunomodulation. PRPs act as cytokine-like molecules supporting balanced Th1/Th2 immune response — relevant to claims of immune adjunct activity but with less rigorous human clinical evidence than the IgG and growth factor mechanisms.
Why bovine colostrum >> human colostrum for IgG
Calves are born with no maternal antibody transfer (placental structure prevents in utero immunoglobulin passage in cattle), so cow colostrum must deliver an enormous IgG dose for newborn calf survival. Human placental anatomy allows transplacental IgG transfer during pregnancy, so human colostrum is much less IgG-concentrated. This is why bovine colostrum has approximately 100× the IgG of human colostrum — an evolutionary accident that makes bovine colostrum a uniquely concentrated source of orally-active immunoglobulins.
Clinical trials
Double-blind placebo-controlled crossover trial in 12 trained volunteers.
12 trained volunteers, double-blind placebo-controlled crossover.
14 days of bovine colostrum or placebo before standardized heavy exercise, with a mean core temperature rise of 1.4°C. The placebo arm showed a 2.5-fold increase in gut permeability post-exercise (lactulose/rhamnose ratio 0.38 to 0.92); colostrum truncated that rise by 80% (0.38 to 0.49). The same paper's cell-culture arm found colostrum increased HSP70 expression and reduced temperature-induced apoptosis in colonic epithelium, an effect blocked by an EGF receptor neutralizing antibody. n=12, and the trial abstract states no dose.
Evidence review and pooled analysis of 5 clinical trials in 152 active adults over 8-12 weeks.
152 active adults
Bovine colostrum reduced days with upper respiratory symptoms by 44% (rate ratio 0.56, 95% CI 0.43-0.72) and symptom episodes by 38% (rate ratio 0.62, 95% CI 0.40-0.99). Four of the five pooled trials were rated at moderate or high risk of bias, most did not reach significance individually, and there were too few data to pool symptom duration. The authors called for an adequately powered trial.
Evidence review and pooled analysis of 10 clinical trials assessing bovine colostrum effects on intestinal permeability via lactulose/rhamnose and lactulose/mannitol ratios.
10 clinical trials pooled
Pooled across 10 trials in healthy athletes plus IBS, NSAID-injury and other patient groups, the 5-hour urinary lactulose/rhamnose ratio fell significantly (mean difference -0.24, 95% CI -0.43 to -0.04), as did the lactulose/mannitol ratio. Heterogeneity was extreme (I² = 99%), meaning the individual trials did not agree with one another, and a blood marker of intestinal cell damage, I-FABP, showed no difference. The authors concluded that more trials varying dose, duration and quality are needed.
Clinical trial in 30 healthy male runners completing 8 weeks of running training 3×/week at lactate threshold while consuming 60 g/day bovine colostrum, whey protein, or control.
30 healthy adult males running 3 times a week for 8 weeks.
After 8 weeks, the lactulose/rhamnose ratio increased significantly more in the colostrum group (+251%) than in the whey group (+21%) or control (-7%). A counterweight to the typical positive findings: high-dose colostrum during sustained training can increase chronic gut permeability, in contrast to the acute benefits seen in shorter crossover designs. The authors note the increase may reflect enhanced transport of large molecules rather than damage, so it should not be read as established harm. Dose and chronic versus acute context appear to matter.